文献速递哮喘

哮喘急性发作新复合终点可加速临床开发:随机对照试验的事后分析

A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials.
PubMed 文献 · Lancet Respir Med · 2017-06-02

该研究基于12项哮喘随机对照试验的数据,构建并验证了一种复合终点CompEx,即日记事件(基于PEF、缓解药使用、症状、觉醒的PRS算法)或严重急性发作的首次发生。

要点

  • CompEx由日记事件(PRS算法)或严重急性发作构成,可替代严重急性发作作为哮喘试验终点。
  • 采用CompEx可使未来药物试验所需患者数平均减少67%,缩短试验 duration。

核心结论

  • CompEx是一种复合终点,可用于评估新型哮喘疗法,允许设计更短、所需患者更少的试验,同时保持显示治疗效应的能力。

研究设计与样本

  • 事后分析,使用12项为期6个月或12个月、标准化收集急性发作和日记卡变量的哮喘试验数据构建和测试CompEx。
  • 研究人群平均年龄35-53岁,女性占59-69%,平均FEV1占预计值百分比为63-84%。
  • 使用5项试验数据建立基于PEF、缓解药使用、症状、觉醒的日记事件算法,并在7项试验中验证CompEx性能。

主要发现

  • 基于PRS的CompEx算法最符合两套标准。
  • 事件数增加及治疗效应维持导致效力大幅净增益,药物试验所需患者数平均减少67%。
  • 在7项比较中的6项,CompEx使所需样本量至少减少50%;独立测试人群验证确认了其增加事件频率、保留治疗效应和减少所需患者数的能力。

关键数值与推荐

  • CompEx定义为日记事件或严重急性发作的首次发生。
  • 日记事件基于峰值呼气流速(P)、缓解药使用(R)、症状(S)、觉醒(A)的阈值和斜率变化评估趋势。

临床怎么用

  • 在哮喘新药临床试验中,可采用CompEx作为终点,以缩短试验 duration 并减少样本量,同时保持检测治疗效应的能力。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Occurrence of severe asthma exacerbations are the cornerstone of the evaluation of asthma management, but severe asthma exacerbations are rare events. Therefore, trials that assess drug efficacy on exacerbations are done late in clinical development programmes. We aimed to establish an endpoint capturing clinically relevant deteriorations (diary events) that, when combined with severe exacerbations, create a composite outcome (CompEx). CompEx needs to strongly mirror results seen with the severe exacerbation-validated outcome, to allow the design of clinical trials of shorter duration and that include fewer patients than trials assessing severe exacerbations. METHODS: Data from 12 asthma trials of 6 months or 12 months duration and, with standardised collection of exacerbations and diary card variables, were used to construct and test CompEx. The study populations had a mean age of 35-53 years, 59-69% were female, and had a mean FEV1 percentage of predicted normal of 63-84%. With data from five trials, we established a series of diary events based on peak expiratory flow (P), reliever use (R), symptoms (S), awakenings (A), and threshold values for change from baseline and slopes to assess trends. For the development phase, we evaluated different variable combinations and deterioration criteria to select the most robust algorithm to define a diary event for the composite outcome. We defined a composite outcome, CompEx, as first occurrence of a diary event or a severe exacerbation. We assessed the performance of CompEx in seven trials by comparing the event frequency, treatment effect (hazard ratio; HR), and the sample size needed for future trials for the CompEx versus episodes of severe exacerbations. FINDINGS: CompEx (based on PRS) was the algorithm that best fulfilled our two-set criteria. When censored at 3 months, CompEx resulted in 2·8 times more events than severe exacerbations, and while preserving the treatment effect observed on severe exacerbations (CompEx over severe exacerbation average HR 1·01). The increased number of events, together with the sustained treatment effect, resulted in a large net gain in power, with a 67% mean reduction in the number of patients required in a drug trial for severe exacerbations. In six of seven comparisons tested, CompEx reduced the sample size needed by at least 50%. Validation of independent test populations confirmed the ability of CompEx to increase event frequencies, preserve treatment effect, and reduce the number of patients needed. INTERPRETATION: CompEx is a composite outcome for evaluation of new asthma therapies. CompEx allows design of shorter trials that require fewer patients than studies of severe exacerbations, while preserving the ability to show a treatment effect compared with severe exacerbations. FUNDING: AstraZeneca.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Fuhlbrigge AL, Bengtsson T, Peterson S, et al. A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials. Lancet Respir Med. 2017. PMID: 28583396. doi:10.1016/S2213-2600(17)30218-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。